Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, filgrastim, methotrexate, allogeneic hematopoietic stem cell transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: 0 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sickle Cell Disease, Stress, Pain
Interventions: Guided Relaxation video clip, Sickle Cell Disease Experience Discussion; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Retinitis Pigmentosa (RP), Usher Syndrome
Interventions: Placebo, NPI-001; Drug
Lead sponsor: Nacuity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Amyloidosis Cardiac
Interventions: Sonotherapy; Combination Product
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemophilia B
Interventions: AAV5-hFIXco-Padua (AMT-061); Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 1 more

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: mycophenolate mofetil, tacrolimus; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glycogen Storage Disease Type III
Interventions: UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker; Biological · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more

Conditions: Congenital Venous Malformation
Interventions: Ethanol 96% Gel, Ethanol 98% Solution; Drug
Lead sponsor: Orfagen; Industry
Eligibility: 12 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, Cardiac Imaging Techniques, Congenital Heart Defects
Interventions: Not listed
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Months and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
Interventions: Follow-up schedule: pre-operative baseline up to 24-months post-procedure; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 23
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 19 more

Conditions: Rett Syndrome
Interventions: NGN-401; Genetic
Lead sponsor: Neurogene Inc.; Industry
Eligibility: 3 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Birmingham, Alabama • Oakland, California • Aurora, Colorado + 10 more

Conditions: Early-Onset Scoliosis Deformity of Spine
Interventions: MAGEC® Spinal Bracing And Distraction System; Device
Lead sponsor: Pediatric Spine Foundation; Other
Eligibility: 5 Years to 9 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Tuberous Sclerosis Complex, Self-injury, Autism
Interventions: Sirolimus, Everolimus; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 2 Years to 30 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Duchenne Muscular Dystrophy
Interventions: givinostat, placebo; Drug
Lead sponsor: Italfarmaco; Industry
Eligibility: 6 Years to 17 Years · Male only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 13
States / cities: Davis, California • San Diego, California • Aurora, Colorado + 10 more

Conditions: Sickle Cell Disease
Interventions: Crovalimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more

Conditions: Congenital Heart Disease (CHD)
Interventions: HeartGPS; Other
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 13 more

Conditions: Muscular Dystrophies, Limb-Girdle
Interventions: SRP-9005, Corticosteroid; Biological · Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Parkinson Disease, Huntington Disease, Autistic Spectrum Disorders, Fragile X Syndrome, Alzheimer Disease, Mild Cognitive Impairment
Interventions: [18F]FPEB; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Developmental Delay Disorders, Chromosome Deletion, Mental Retardation, Sleep Disorders, Circadian Rhythm, Self Injurious Behavior
Interventions: dTR Melatonin (NIH CC PDS), Phototherapy (Bright Light), Melatonin CR; Drug · Device
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia, Sickle Cell
Interventions: Types of Telemedicine Delivery Models; Other
Lead sponsor: Indiana University; Other
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Laxity; Skin
Interventions: HighThroughput Micro Coring Device; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Sacramento, California • Miami, Florida • New York, New York + 2 more

Conditions: Cystic Fibrosis
Interventions: TEZ, IVA, VX-440, Matched Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 22
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more

Conditions: Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions: Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Congenital Heart Defect, Cardiopulmonary Bypass, Inflammatory Response, Low Cardiac Output Syndrome, Inflammation
Interventions: Single blood draw, Multiple blood draws; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: Up to 6 Months
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Ultrasound Therapy In Cardiac Amyloidosis

Dose Confirmation Trial of AAV5-hFIXco-Padua

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.

MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients

The Ailliance Post-Market Clinical Study

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

Hospital-Based Cluster Trial: Magnetically Controlled Growing Rods Using Distraction Intervals

Rapalogues for Autism Phenotype in TSC: A Feasibility Study

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)

A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

Treatment Strategies for Children With Smith-Magenis Syndrome

Telemedicine for Children With Sickle Cell Disease

Efficacy of Micro-excisional Skin Removal by Micro-coring Device in Treatment of Wrinkles and Laxity of Face and Neck

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass